Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 20,682 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Chronic Lymphocytic Leukemia
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Months
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 8 more

Conditions: Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
Interventions: Intraarterial Cetxuimab (Erbitux); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Oral OKT3, Omeprazole; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions: cetuximab, gemcitabine hydrochloride, capecitabine, radiation therapy, bevacizumab, laboratory biomarker analysis; Biological · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia
Interventions: CMC-544 (Inotuzumab Ozogamycin), Rituximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease
Interventions: AG-348; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Moyamoya Syndrome, Moyamoya Disease, Atheroscleroses, Cerebral
Interventions: Soterix® 4x1HD-TDCS, Soterix® 1x1 tDCS, Cognitive training program; Device · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sickle Cell Disease, Pregnancy Related
Interventions: Prophylactic Transfusion Intervention group: Transfusion, Control group; Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
Interventions: enadenotucirev, nivolumab; Biological
Lead sponsor: Akamis Bio; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more

Conditions: COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
Interventions: Blood and nasal swab sampling; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Sylmar, California • Torrance, California + 3 more

Conditions: Malignant Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Bone density and carotid ultrasound; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity & Overweight, Obese Adolescents, Metabolic Abnormalities
Interventions: Use of an unblinded CGM device; Device
Lead sponsor: University of Florida; Other
Eligibility: 13 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Graft Versus Host Disease
Interventions: Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Gainesville, Florida • Tampa, Florida • Boston, Massachusetts + 6 more

Conditions: Lymphoma, B-Cell, Follicular Lymphoma
Interventions: Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hyperinsulinism, Diabetes, Pancreatic Diseases, Pancreatectomy; Hyperglycemia
Interventions: Bihormonal Bionic Pancreas; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Extensive-stage Small-cell Lung Cancer, Liver Metastases
Interventions: Bevacizumab; Drug
Lead sponsor: Kamya Sankar; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Blood Loss
Interventions: Hemostatic Matrix; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: Not listed
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Filgrastim, Melphalan, Rituximab, Umbilical Cord Blood-derived Natural Killer Cells; Procedure · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metabolism of Prostaglandin D2
Interventions: niacin, aspirin, PGD2; Dietary Supplement · Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colorectal Carcinoma, Lynch Syndrome
Interventions: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
Interventions: NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg); Drug
Lead sponsor: Amr Mohamed MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Understanding Chronic Lymphocytic Leukemia

Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Oral OKT3 for the Treatment of Active Ulcerative Colitis

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

A Dose-Finding Study of AG-348 in Sickle Cell Disease

A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion

Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

COVID-19 Outcome Prediction Algorithm

Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy

Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes

A Study Comparing Continuous Glucose Monitoring Augmented Nutritional Counseling and Standard of Care Treatment Strategies in a Three-Month Nutrition Intervention

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Pathways of Eicosanoid Metabolism

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas